FDA
FDA Articles
Teva Pharmaceutical announced on Monday that the FDA approved the first generic equivalent to Nexium delayed-release capsules in the United States.
Published:
GW Pharmaceuticals reported top-line results from the first of three Phase 3 trials for Sativex.
Published:
What are investors, and patients, supposed to think when is launching a generic version of Diovan?
Published:
Last Updated:
Analysts are beginning to make their calls for what the future will hold for Gilead Sciences, AbbVie and Express Scripts.
Published:
AbbVie and Express Scripts have entered into an exclusive agreement under which Express Scripts will distribute AbbVie's hepatitis treatment.
Published:
A biosimilar application filing from Apotex has been accepted by the Food and Drug Administration for version of Amgen's Neulasta.
Published:
While this was generally a known event coming down the pipe, arthritis drug Celebrex now has a generic competitor in America.
Published:
Array BioPharma has announced that it had reached a definitive agreement with Novartis to regain full worldwide rights to cancer drug binimetinib.
Published:
Avanir Pharmaceuticals announced that it has entered into a definitive agreement with Otsuka Pharmaceutical for a $17.00 per share buyout.
Published:
On Monday, Sunesis made an announcement that it would be making a presentation regarding its drug candidates vosaroxin and cytarabine.
Published:
Geron hasannounced that it entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech to develop and commercialize imetelstat.
Published:
The FDA gave Geron some good news Monday morning when it removed the clinical hold on the its investigational new drug application for imetelstat.
Published:
Durect and Pain Therapeutics have been stung by Pfizer's decision to discontinue to develop Remoxy.
Published:
Sarepta Therapeutics shares took a big hit on Monday morning as disappointing news started its week out on the wrong foot.
Published:
Alcobra recently posted news of an FDA trial and its shares traded down about 50% Monday morning.
Published:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.